Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.
Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV. Swerdlow AJ, et al. Among authors: hoskin pj. J Clin Oncol. 2012 Aug 1;30(22):2745-52. doi: 10.1200/JCO.2011.38.8835. Epub 2012 Jun 25. J Clin Oncol. 2012. PMID: 22734026
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
Linch DC, Vaughan Hudson B, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan DW, Stevenson PA, Wood JK, MacLennan KA, Anderson L, Gregory WM, Vaughan Hudson G. Linch DC, et al. Among authors: hoskin pj. Br J Cancer. 1996 Jul;74(2):318-22. doi: 10.1038/bjc.1996.360. Br J Cancer. 1996. PMID: 8688344 Free PMC article. Clinical Trial.
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC. Harrison CN, et al. Br J Cancer. 1999 Oct;81(3):476-83. doi: 10.1038/sj.bjc.6690718. Br J Cancer. 1999. PMID: 10507773 Free PMC article.
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Vaughan G, Hudson, Linch DC; British National Lymphoma Investigation. Ardeshna KM, et al. Among authors: hoskin pj. Lancet. 2003 Aug 16;362(9383):516-22. doi: 10.1016/s0140-6736(03)14110-4. Lancet. 2003. PMID: 12932382 Clinical Trial.
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S, Mackinnon S, Hoskin PJ, Goldstone AH, Linch DC. Ardeshna KM, et al. Among authors: hoskin pj. Br J Haematol. 2005 Aug;130(3):363-72. doi: 10.1111/j.1365-2141.2005.05603.x. Br J Haematol. 2005. PMID: 16042685 Free article.
532 results